Chinese Hepatolgy ›› 2026, Vol. 31 ›› Issue (9): 1293-1298.

• Liver Cancer • Previous Articles     Next Articles

Translational therapeutic effect of percutaneous radiofrequency ablation-assisted modified two-step hepatectomy with liver separation in the treatment of borderline resectable liver cancer

Chen Yao1, He Yan'an1, Tang Bo1, Zhu Yong2   

  1. 1. Department of Hepatobiliary Surgery, Jiangyou People's Hospital, Mianyang 621799,China;
    2. Department of Hepatobiliary Surgery,Chengdu Fifth People's Hospital, Chengdu 611130,China
  • Received:2025-10-16 Online:2026-09-30 Published:2026-11-16
  • Contact: Chen Yao,Email: nnnb6fl@163.com

Abstract: Objective This study aimed to explore the translational therapeutic effect of percutaneous radiofrequency ablation (PRFA) -assisted modified two-step hepatectomy with liver separation in the treatment of borderline resectable liver cancer. Methods A prospective cohort study was conducted on 86 patients with borderline resectable liver cancer admitted to Jiangyou People's Hospital, Sichuan Province from March 2022 to March 2024. They were randomly divided into 2 groups by the random number table method. The control group (n=43) underwent traditional associating liver partition and portal vein ligation for staged hepatectomy (ALPPS). The observation group (n=43) used PRFA-assisted liver separation in the first stage of ALPPS. The perioperative indicators of the patients were statistically analyzed. The changes in liver function and liver volume after surgery between the two groups were compared, and the postoperative complications of the patients were statistically analyzed. All patients were followed up for one year, and the recurrence and progression-free survival of the patients during this period were statistically analyzed. Results Compared with the control group, the operation time of the first stage [(217.26±35.37) vs. (141.22±23.54) h], intraoperative blood loss [(378.56±85.46) vs. (95.33±10.29) mL], incision length [(23.97±4.35) vs. (17.25±3.66) cm], intraoperative blood loss in the second stage [(638.71±85.43) vs. (545.26±80.95) mL], the interval between procedures [(18.26±3.71) vs. (15.21±4.95) d] and length of hospital stay [(15.95±2.06) vs. (13.35±2.33) d] were shortened (P<0.05). Compared with the control group, the levels of ALT and AST in the observation group increased [(659.43±61.26) vs. (890.56±55.79) U/L at 1 day after the first stage of operation (584.59±62.43) vs.(675.56±96.51) U/L](P<0.05). There was no statistically significant difference in FLR and F/S levels between the two groups at each time point (P<0.05). The total incidence of postoperative bile leakage and postoperative complications in the observation group was lower than that in the control group (13.95% vs.0; 41.86% vs. 16.28%) (P<0.05). The postoperative recurrence rate in the observation group (17.50%) was lower than that in the control group (21.05%) (χ2=0.158, P=0.691). Kaplan-Meier survival analysis showed that there was no statistically significant difference in the progression-free survival curves between the two groups (Log-Rank χ2=0.121, P=0.718). Conclusion PRFA-assisted ALPPS in the treatment of borderline resectable liver cancer patients can reduce intraoperative blood loss and incision length, shorten operation time, operation interval and hospital stay, increase postoperative liver volume, and reduce the occurrence of primary complications.

Key words: Percutaneous radiofrequency ablation, Associating liver partition and portal vein ligation for staged hepatectomy, Borderline resectable, Liver cancer, Residual liver volume